Ulysses Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$385K Buy
+2,000
New +$216K 0.05% 39
2023
Q3
– Sell
-5,100
Closed -$620K – 53
2023
Q2
$620K Buy
+5,100
New +$680K 0.06% 41
2023
Q1
– Sell
-6,000
Closed -$1.08M – 56
2022
Q4
$1.08M Sell
6,000
-3,000
-33% -$491K 0.26% 30
2022
Q3
$1.06M Buy
+9,000
New +$1.37M 0.15% 33

Other funds holding MRNA

Ulysses Management's MRNA Position: Q3 2026 in Review

Ulysses Management opened a new position in Moderna (MRNA) in Q3 2026: 2,000 shares worth $385K. The stake represents 0.05% of the portfolio and ranks #39 among its holdings. This is a return to the name: Ulysses Management previously reported a position in MRNA as recently as Q2 2023.

Ulysses Management first reported a position in MRNA in Q3 2022 and has held it in 4 quarters since. The position peaked at $1.08M in Q4 2022. 1,044 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Ulysses Management held 2,000 shares of Moderna worth $385K as of Q3 2026.
  • Moderna was a new Ulysses Management position in Q3 2026.
  • Moderna made up 0.05% of Ulysses Management's portfolio in Q3 2026, its #39 holding.
  • Ulysses Management first reported a position in Moderna in Q3 2022 and has held it in 4 quarters since.
  • Ulysses Management's Moderna position peaked at $1.08M in Q4 2022.
  • 1,044 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Ulysses Management's 13F filing for Q3 2026, filed 16 Nov 2026.